<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="21683">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01889212</url>
  </required_header>
  <id_info>
    <org_study_id>1-10-72-19-12</org_study_id>
    <nct_id>NCT01889212</nct_id>
  </id_info>
  <brief_title>Imaging With 11C-erlotinib PET/CT to Identify Responders to Erlotinib Treatment in NSCLC</brief_title>
  <official_title>Imaging With 11C-erlotinib PET/CT to Identify Responders to Erlotinib Treatment in NSCLC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <authority>Denmark: The Regional Committee on Biomedical Research Ethics</authority>
    <authority>Denmark: Danish Dataprotection Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      New treatment strategies have been developed in lung cancer targeting the Epidermal Growth
      Factor Receptor (EGFR). Patients with an activating mutation in the EGFR have high responds
      rates to the treatment and should be treated with a EGFR inhibitor as first line of
      treatment. Some wild type patients do as well respond but selection of these patients is
      more difficult.

      Erlotinib has been labeling with 11C and used as a new PET tracer. Accumulation of the
      tracer (11C-erlotinib) in tumors has showed promising results for selection of responders.

      The investigators now want to conduct a larger clinical study to evaluate if accumulation of
      tracer on a pre-treatment 11C-erlotinib PET/CT can predict responds to erlotinib.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">April 2015</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Accumulation of 11c-erlotinib in tumors before and after treatment with erlotinib</measure>
    <time_frame>From date of inclusion until the date of first documented progression on the erlotinib treatment or date of death, whichever came first, assessed up to 30 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Accumulation of 11c-erlotinib in tumors will be correlated to PFS on erlotinib treatment.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>NSCLC, erlotinib treatment, 11C-erlotinib PET/CT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>11C-erlotinib PET/CT</intervention_name>
    <arm_group_label>NSCLC, erlotinib treatment, 11C-erlotinib PET/CT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Lung Cancer patients with non-small cell histology and stage IV disease who are
             candidate for erlotinib treatment as first/ second/ third line of treatment

        Exclusion Criteria:

          -  pregnancy

          -  severe dyspnoea
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Meldgaard, Ph.D MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aarhus University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anne Winther Larsen, MD</last_name>
    <email>anlarsen@rm.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Peter Meldgaard, Ph.D</last_name>
    <email>petemeld@rm.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Deparment of oncology, Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Winther Larsen, MD</last_name>
      <email>anlarsen@rm.dk</email>
    </contact>
    <contact_backup>
      <last_name>Peter Meldgaard, Phd</last_name>
      <email>petemeld@rm.dk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/22095231</url>
  </link>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>June 25, 2013</lastchanged_date>
  <firstreceived_date>June 3, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Erlotinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
